Biogen
BIIB Nasdaq· Biotechnology
Last close · Oct 27, 2026
$252.73
KIRA · Stoqly’s AI analyst, in plain words
- Biogen had $9.9B of revenue in fiscal 2025, up 2.2% on the year before. Over five years, revenue changed −6.0% a year on average.
- Biogen made $1.3B of net profit in fiscal 2025. From fiscal 2016 to 2025, diluted EPS grew −7.0% a year.
- Free cash flow was $2.1B in fiscal 2025, 20.7% of revenue.
- Biogen returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count rose 0.8%.
- Biogen owes $2.5B more than it holds in cash, about 1.0 years of operating profit.
Market cap
$37.5B
P/E
27.2x
Revenue
$9.9B
Net income
$1.3B
Free cash flow
$2.1B
Operating margin
—
Biogen in 30 seconds · fiscal 2025
Are sales growing?
+2.2%
Only a little. Sales grew 2.2% last year.
Does it make a profit?
13.1%
Yes. It keeps 13.1% of every sale as profit.
Does profit turn into cash?
20.7%
Yes. 20.7% of sales ends up as free cash.
Is debt under control?
1.0x
Yes. It could repay its debt with 1.0 years of operating profit.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
27.2x
One share costs 27.2 times its yearly profit per share. Typical for its sector: 28.4x.
What Biogen does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 6, 2026
- Legal name
- BIOGEN INC.
- CIK
- 0000875045
Biogen · BIIB
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $11.0B | $10.2B | $9.8B | $9.7B | $9.9B |
| Revenue growth | −18.3% | −7.4% | −3.3% | −1.6% | 2.2% |
| Gross margin | 80.8% | 77.6% | 74.2% | 76.1% | 75.7% |
| Operating margin | 25.9% | — | — | — | — |
| Net income | $1.6B | $3.0B | $1.2B | $1.6B | $1.3B |
| Net margin | 14.2% | 30.0% | 11.8% | 16.9% | 13.1% |
| Diluted EPS | $10.40 | $20.87 | $7.97 | $11.18 | $8.79 |
| Cash | |||||
| Cash from operations | $3.6B | $1.4B | $1.5B | $2.9B | $2.2B |
| Capital expenditure | $258M | $240M | $277M | $154M | $154M |
| Free cash flow | $3.4B | $1.1B | $1.3B | $2.7B | $2.1B |
| FCF margin | 30.8% | 11.3% | 12.9% | 28.1% | 20.7% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $1.8B | $750M | $0.0M | $0.0M | $0.0M |
| Share count change | −7.3% | −2.4% | −0.3% | 0.2% | 0.8% |
| Debt and strength | |||||
| Cash and short-term investments | $3.8B | $4.9B | $1.0B | $2.4B | $3.8B |
| Debt incl. finance leases | $6.3B | $6.3B | $6.9B | $6.3B | $6.3B |
| Shareholders' equity | $10.9B | $13.4B | $14.8B | $16.7B | $18.3B |
| Net debt / EBITDA | 0.7x | 0.3x | 2.9x | 1.4x | 1.0x |
| Current ratio | 1.8x | 3.0x | 2.0x | 1.4x | 2.7x |
| Interest coverage | 11.2x | 15.6x | 6.3x | 8.6x | 6.8x |
| Returns and quality | |||||
| Return on capital | 19.1% | 22.4% | 7.8% | 8.9% | 7.3% |
| Return on equity | 14.4% | 25.1% | 8.2% | 10.4% | 7.4% |
| Piotroski F-score | 5 | 5 | 4 | 6 | 5 |
| Altman Z'' | 4.6 | 6.2 | 4.7 | 4.8 | 5.7 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.9M
2 insiders
Of sales under plans
100%
$0.9M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Biogen · BIIB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Biogen BIIB | $37.5B | 2.2% | — | 20.7% | 7.3% | 27.2x | 5 |
| Vertex Pharmaceuticals VRTX | $133.0B | 8.9% | 34.8% | 26.6% | 31.5% | 30.3x | 6 |
| Regeneron Pharmaceuticals REGN | $86.5B | 1.0% | 25.0% | 28.5% | 12.7% | 20.2x | 5 |
| Incyte INCY | $24.1B | 21.2% | 29.5% | 26.4% | 79.4% | 16.5x | 8 |
| Gilead Sciences GILD | $197.7B | 2.4% | 34.0% | 32.1% | 23.0% | — | 8 |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $252.73 a share, the company is worth $37.5B: 27.2 times its earnings of the last four quarters.
Biogen grew sales faster than 1 of its 4 similar companies. Its P/E is higher than 2 of 3.
Source: SEC EDGAR XBRL filings (CIK 0000875045). Data updated October 9, 2026. For information only — not investment advice. Check the original filings before relying on any figure.